Amgen Inc. Files Definitive Proxy Materials

TL;DR

Amgen filed its final proxy docs, get ready to vote.

AI Summary

Amgen Inc. filed a Definitive Additional Materials proxy statement on April 29, 2025. This filing is related to the company's proxy statement and is not a preliminary or confidential version. Amgen Inc. is a biotechnology company incorporated in Delaware.

Why It Matters

This filing indicates that Amgen is proceeding with its shareholder communication and voting process, which is a standard part of corporate governance for publicly traded companies.

Risk Assessment

Risk Level: low — This is a routine regulatory filing for a large, established company and does not contain new material information that would inherently increase risk.

Key Players & Entities

• AMGEN INC. (company) — Registrant
• 0000950170-25-060241 (filing_id) — Accession Number
• 20250429 (date) — Filing Date
• DE (state) — State of Incorporation
• 1934 Act (regulation) — SEC Act

FAQ

From the Filing

0000950170-25-060241.txt : 20250429 0000950170-25-060241.hdr.sgml : 20250429 20250429164052 ACCESSION NUMBER: 0000950170-25-060241 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 4 FILED AS OF DATE: 20250429 DATE AS OF CHANGE: 20250429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 25888530 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 DEFA14A 1 amgn_top_100_defa_14a_20.htm DEFA14A DEFA14A       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑   Filed by the registrant       ☐  Filed by a party other than the registrant   Check the appropriate box:       ☐ Preliminary Proxy Statement       ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2))       ☐ Definitive Proxy Statement       ☑ Definitive Additional Materials       ☐ Soliciting Material Pursuant to Section 240.14a-12     AMGEN INC. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant)   Payment of filing fee (check the appropriate box):       ☑ No fee required.       ☐ Fee paid previously with preliminary materials.       ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.   Subsequent to this filing, the following letter was sent by Amgen Inc. to certain institutional holders of our common stock. We encourage our stockholders to similarly consider this letter when casting their vote.   Amgen Inc. One Amgen Center Drive Thousand Oaks, CA 91320 USA (805) 447-1000   amgen.com       «DATE»   «SALUTATION» «FIRSTNAME» «LASTNAME» «COMPANYNAME» «ADDRESS1» «ADDRESS2» «CITY», «STATE» «ZIPCODE»   Dear «SALUTATION» «LASTNAME»:   I want to take a moment to thank you for your investment in Amgen. I typically write around this time of year to provide a short summary of Amgen’s Board of Directors’ recommendations for our Annual Meeting of Stockholders. 2024 was another year of strong execution as we delivered record annual sales for twenty-one of our products and an ambitious research and development program agenda across our four therapeutic areas ( General Medicine , Rare Disease , Oncology , and Inflammation ).   Highlights for the year include: • In General Medicine , based on positive MariTide TM ( maridebart cafraglutide ) Phase 2 data in chronic weight management, we initiated two Phase 3 MariTide clinical trials in adults living with obesity or overweight, with or without Type 2 diabetes in March 2025. A Phase 3 study of olpasiran in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein(a) (Lp(a)) continued to progress, moving us closer to what we hope will be a medicine to reduce cardiovascular risk for patients with Lp(a) elevation. • In Rare Disease , TEPEZZA® ( 1 ) was launched in Japan for the treatment of thyroid eye disease (TED),